Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Longitudinal Outcomes of Chronically Transfused Adults with Sickle Cell Anemia and a History of Childhood Stroke

Jennifer M Jones, Julia Wool, Elizabeth P Crowe, Evan Bloch, Lydia H. Pecker, Sophie M. Lanzkron

Blood (2022) 140 (Supplement 1): 8013–8014.

https://doi.org/10.1182/blood-2022-160471

Published: 2022

Journal Articles

Blood Conservation Strategies in Adult Sickle Cell Patients on Chronic Transfusion Therapy: A Single Center Experience

Jennifer M Jones, Ariel Swett, Courtney Elizabeth Lawrence, Evan Bloch, Sophie M. Lanzkron

Blood (2021) 138 (Supplement 1): 1894.

https://doi.org/10.1182/blood-2021-153245

Published: 2021

Journal Articles

Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function

Blood (2021) 137 (18): 2450–2462.

https://doi.org/10.1182/blood.2020009620

Published: 2021

Includes: Supplemental data

Journal Articles

The Incidence and Associated Risk Factors in Central Venous Catheter Associated Infectious Complications within the Autologous Stem Cell Transplant Population of Eastern Health

Tom Dunne, B.Comm (Hons), MD, David M. Jones, MD

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-142722

Published: 2020

Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Blood (2019) 134 (Supplement_1): 3934.

https://doi.org/10.1182/blood-2019-124178

Published: 2019

Journal Articles

Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma

Bruno M. Grande, Daniela S. Gerhard, Aixiang Jiang, Nicholas B. Griner, Jeremy S. Abramson, Thomas B. Alexander, Hilary Allen, Leona W. Ayers, Jeffrey M. Bethony, Kishor Bhatia, Jay Bowen, Corey Casper, John Kim Choi, Luka Culibrk, Tanja M. Davidsen, Maureen A. Dyer, Julie M. Gastier-Foster, Patee Gesuwan, Timothy C. Greiner, Thomas G. Gross, Benjamin Hanf, Nancy Lee Harris, Yiwen He, John D. Irvin, Elaine S. Jaffe, Steven J. M. Jones, Patrick Kerchan, Nicole Knoetze, Fabio E. Leal, Tara M. Lichtenberg, Yussanne Ma, Jean Paul Martin, Marie-Reine Martin, Sam M. Mbulaiteye, Charles G. Mullighan, Andrew J. Mungall, Constance Namirembe, Karen Novik, Ariela Noy, Martin D. Ogwang, Abraham Omoding, Jackson Orem, Steven J. Reynolds, Christopher K. Rushton, John T. Sandlund, Roland Schmitz, Cynthia Taylor, Wyndham H. Wilson, George W. Wright, Eric Y. Zhao, Marco A. Marra, Ryan D. Morin, Louis M. Staudt

Blood (2019) 133 (12): 1313–1324.

https://doi.org/10.1182/blood-2018-09-871418

Published: 2019

Includes: Supplemental data

Journal Articles

Exceptional Responses to Epigenetic Based Therapy in Pediatric and Young Adult Monosomy 7 MDS/AML Patients with and without TP53 Mutations

LaQuita M Jones, DO, Maureen M O'Brien, MD, Erin H. Breese, MD PhD, Karen Burns, MD, Jennifer Mangino, MD, Michael J. Absalon, MD PhD, Javier A. El-Bietar, MD, Michael Grimley, MD, Benjamin Mizukawa, MD, Lynn Lee, MD, John Peter Perentesis, MD, Christine L Phillips, MD

Blood (2017) 130 (Supplement 1): 3895.

https://doi.org/10.1182/blood.V130.Suppl_1.3895.3895

Published: 2017

Journal Articles

Outcomes and Impact of Donor Lymphocyte Infusion after Reduced Intensity Conditioned-Alemtuzumab Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Mature Lymphoid Malignancies

Charlotte K. Brierley, MD, Francesca M Jones, MD, Katherine Hanlon, MD, Andrew Peniket, MD, Patrick Medd, MD PhD, Andrew Clark, MD, Anne Parker, MD, Sridhar Chaganti, MD PhD, Ram Malladi, MD PhD, Charles Craddock, MD PhD, Robert Danby, MD PhD, Vanderson Rocha, MD PhD

Blood (2016) 128 (22): 3500.

https://doi.org/10.1182/blood.V128.22.3500.3500

Published: 2016

Journal Articles

Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study

Jean-Jacques Kiladjian, MD PhD, Tamás Masszi, MD PhD, Mark M. Jones, MD, Brian Gadbaw, MD, Jingjin Li, PhD, Dany Habr, MD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD

Blood (2015) 126 (23): 2804.

https://doi.org/10.1182/blood.V126.23.2804.2804

Published: 2015

Journal Articles

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Claire N. Harrison, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Laurent Knoops, MD PhD, Francisco Cervantes, Mark M. Jones, MD, Kang Sun, PhD, Laurence Descamps, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Tiziano Barbui, MD

Blood (2015) 126 (23): 59.

https://doi.org/10.1182/blood.V126.23.59.59

Published: 2015

Journal Articles

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Ruben Mesa, MD, Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N. Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Shui He, PhD, Mark M Jones, MD, Shreekant Parasuraman, PhD, Jingjin Li, PhD, Isabelle Côté, MD, Dany Habr, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 709.

https://doi.org/10.1182/blood.V124.21.709.709

Published: 2014

Journal Articles

Ruxolitinib Efficacy By Hematocrit Control in Patients with Polycythemia Vera: An Analysis of the RESPONSE Trial

Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Ruben Mesa, MD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 3201.

https://doi.org/10.1182/blood.V124.21.3201.3201

Published: 2014

Journal Articles

The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF)

Ruben Mesa, MD, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD MB, Pierre Zachee, MD PhD, Mamta Garg, MD FRCP, FRCPath, Roger Lyons, MD, Silwan Chedid, MD, Steffen Koschmieder, MD, Ciro Rinaldi, MD PhD, Jennifer Byrne, MB, ChB, PhD FRCP, FRCPath, Yasmin Hasan, MD, Francesco Passamonti, MD, Srdan Verstovsek, MD PhD, Deborah Hunter, PhD, Mark M Jones, MD, Shui He, PhD, Alex Morozov, MD PhD, Bruno Martino, MD

Blood (2014) 124 (21): 3168.

https://doi.org/10.1182/blood.V124.21.3168.3168

Published: 2014

Journal Articles

Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial

Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Ruben Mesa, MD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3181.

https://doi.org/10.1182/blood.V124.21.3181.3181

Published: 2014

Journal Articles

Efficacy of Ruxolitinib By Baseline Spleen Volume in Patients with Polycythemia Vera Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Jean-Jacques Kiladjian, MD PhD

Blood (2014) 124 (21): 1840.

https://doi.org/10.1182/blood.V124.21.1840.1840

Published: 2014

Journal Articles

Prior Granulocyte Colony-Stimulating Factor Treatment Enhances the Immediate and Transient Output of Primitive Hematopoietic Cells in the Blood of Normal Adult Human Donors Treated with Plerixafor

Paul H. Miller, Naoto Nakamichi, MDPhD, Gabrielle Rabu, Kirk R. Schultz, MD, David M. Jones, MD, Stephen Couban, MD FRCPC, Connie J. Eaves, PhD

Blood (2014) 124 (21): 5787.

https://doi.org/10.1182/blood.V124.21.5787.5787

Published: 2014

Journal Articles

Clinical and Correlative Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Previously Untreated Indolent Non-Hodgkin Lymphoma

Xiao-Dong Li, PhD, Ann Brunson, BS, Robert o'Donnell, Professor, Kelly M Jones, BS, Richard B Pollard, Joseph Tuscano, MD

Blood (2014) 124 (21): 4477.

https://doi.org/10.1182/blood.V124.21.4477.4477

Published: 2014

Journal Articles

Analysis of FOXO1 mutations in diffuse large B-cell lymphoma

Diane L. Trinh, David W. Scott, Ryan D. Morin, Maria Mendez-Lago, Jianghong An, Steven J. M. Jones, Andrew J. Mungall, Yongjun Zhao, Jacqueline Schein, Christian Steidl, Joseph M. Connors, Randy D. Gascoyne, Marco A. Marra

Blood (2013) 121 (18): 3666–3674.

https://doi.org/10.1182/blood-2013-01-479865

Published: 2013

Includes: Supplemental data

Journal Articles

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

Lia Gore, MD, Margaret E. Macy, M.D., Francoise Mechinaud, MD, Aru Narendran, MD, PhD, Frank Alvaro, MD, Carola A.S. Arndt, MD, Phillip Barnette, MD, Jessica Boklan, MD, Todd Cooper, DO, Laura Martin, MD, W Tcheng, MD, Peter Tarassoff, MD, Mark M Jones, MD, Soheil Meshinchi, MD, PhD, Robert J. Arceci, MD, PhD

Blood (2012) 120 (21): 1517.

https://doi.org/10.1182/blood.V120.21.1517.1517

Published: 2012

Journal Articles

A Post Hoc Landmark Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Xavier Thomas, MD, Christopher Arthur, MD, Jacques Delaunay, MD, Mark M Jones, MD, Erhan Barrak, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 3623.

https://doi.org/10.1182/blood.V120.21.3623.3623

Published: 2012

NARROW

Longitudinal Outcomes of Chronically Transfused Adults with Sickle Cell Anemia and a History of Childhood Stroke

Blood Conservation Strategies in Adult Sickle Cell Patients on Chronic Transfusion Therapy: A Single Center Experience

Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function

The Incidence and Associated Risk Factors in Central Venous Catheter Associated Infectious Complications within the Autologous Stem Cell Transplant Population of Eastern Health

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma

Exceptional Responses to Epigenetic Based Therapy in Pediatric and Young Adult Monosomy 7 MDS/AML Patients with and without TP53 Mutations

Outcomes and Impact of Donor Lymphocyte Infusion after Reduced Intensity Conditioned-Alemtuzumab Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Mature Lymphoid Malignancies

Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Ruxolitinib Efficacy By Hematocrit Control in Patients with Polycythemia Vera: An Analysis of the RESPONSE Trial

The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF)

Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial

Efficacy of Ruxolitinib By Baseline Spleen Volume in Patients with Polycythemia Vera Resistant to or Intolerant of Hydroxyurea

Prior Granulocyte Colony-Stimulating Factor Treatment Enhances the Immediate and Transient Output of Primitive Hematopoietic Cells in the Blood of Normal Adult Human Donors Treated with Plerixafor

Clinical and Correlative Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Previously Untreated Indolent Non-Hodgkin Lymphoma

Analysis of FOXO1 mutations in diffuse large B-cell lymphoma

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

A Post Hoc Landmark Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only